Grand Pharmaceutical Group
↗Wuhan, China
Grand Pharmaceutical Group is a diversified, innovation-driven international pharmaceutical company listed on the Hong Kong Stock Exchange. The company focuses on three core areas: pharmaceutical technology, nuclear medicine anti-tumor diagnosis and treatment, and cerebro-cardiovascular precision interventional technology. It has established a significant global presence through strategic acquisitions and licensing deals, particularly in the field of Radionuclide Drug Conjugates (RDC).
The Group operates a comprehensive industrial chain covering R&D, manufacturing, and sales. Its product portfolio includes high-end medical devices, innovative drugs for oncology, ophthalmology, ENT, and cardiovascular emergency preparations. Grand Pharma has actively expanded its innovative pipeline through partnerships with global leaders like Telix Pharmaceuticals, ITM, and Sirtex Medical.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Nuclear Medicine & Precision Intervention
SIZE & FINANCIALS
Employees:10000+
Revenue:$1B - $2B USD (HKD 11.64B in 2024)
Founded:1939
Ownership:public
Status:operating
FUNDING
Stage:Public
Investors:China Grand Enterprise, Public Shareholders
STOCK
Exchange:HKEX
Ticker:0512
Market Cap:~$1.5B - $2.0B USD (approx. HKD 12B - 15B)
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial / Phase 3
Modalities:Small molecule, Radionuclide Drug Conjugates (RDC), mRNA, Medical Devices, Peptides
Active Trials:30
Trial Phases:Phase 1: 12 | Phase 2: 8 | Phase 3: 10 | Phase 4: 2
FDA Approvals:2
EMA Approvals:1
CORPORATE STRUCTURE
Parent Company:China Grand Enterprise (CGE)
Subsidiaries:Grandpharma (China) Co., Ltd., Sirtex Medical, Grand Medical Pty Ltd, OncoSec Medical (Associate)
Key Partnerships:Telix Pharmaceuticals (RDC development), ITM Isotope Technologies Munich (Targeted Radionuclide Therapy), Sirtex Medical (Y-90 Microspheres), IRE ELiT (Radioisotope supply), Novavax (COVID-19 vaccine distribution in China)
COMPETITION
Position:Leader
Competitors:Jiangsu Hengrui Pharmaceuticals, Sino Biopharmaceutical, Shanghai Fosun Pharmaceutical, BeiGene
LEADERSHIP
Key Executives:
Dr. Tang Weikun - Chairman
Dr. Shao Yan - CEO
Board Members:Liu Chengwei, Hu Bo, Dr. Shao Yan, Dr. Niu Zhanqi
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Grand Pharmaceutical Group. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.